CO2022014199A2 - Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19 - Google Patents

Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19

Info

Publication number
CO2022014199A2
CO2022014199A2 CONC2022/0014199A CO2022014199A CO2022014199A2 CO 2022014199 A2 CO2022014199 A2 CO 2022014199A2 CO 2022014199 A CO2022014199 A CO 2022014199A CO 2022014199 A2 CO2022014199 A2 CO 2022014199A2
Authority
CO
Colombia
Prior art keywords
coronavirus
treating
methods
negative effects
antibody compositions
Prior art date
Application number
CONC2022/0014199A
Other languages
English (en)
Inventor
Monzón Kalet León
Pradip Nair
Jose Enrique Montero Casimiro
Shaw Kiran Mazumdar
Usha Bughani
Sandeep Nilkanth Athalye
Melarkode Subbaraman Ramakrishnan
Ramos Tania Crombet
Suzarte Mayra Ramos
Original Assignee
Biocon Ltd
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Biocon Ltd, Ct Inmunologia Molecular filed Critical Biocon Ltd
Publication of CO2022014199A2 publication Critical patent/CO2022014199A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona el uso de anticuerpos anti-CD6 que se unen específicamente al dominio 1 de CD6 para tratar los efectos de un coronavirus o agente bacteriano y particularmente el COVID-19 y las variantes del mismo. Los anticuerpos anti-CD6 de la presente invención exhiben actividad terapéutica al reducir la respuesta inmune hiperactiva, tal como los niveles de alta expresión de citocinas.
CONC2022/0014199A 2020-04-04 2022-10-04 Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19 CO2022014199A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
CO2022014199A2 true CO2022014199A2 (es) 2022-11-08

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014199A CO2022014199A2 (es) 2020-04-04 2022-10-04 Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19

Country Status (14)

Country Link
US (1) US20230151107A1 (es)
EP (1) EP4126961A1 (es)
JP (1) JP2023526890A (es)
KR (1) KR20220165267A (es)
CN (1) CN115698071A (es)
AU (1) AU2021247258A1 (es)
BR (1) BR112022018936A2 (es)
CA (1) CA3174566A1 (es)
CL (1) CL2022002684A1 (es)
CO (1) CO2022014199A2 (es)
IL (1) IL296487A (es)
MX (1) MX2022012229A (es)
TW (1) TW202200202A (es)
WO (1) WO2021199006A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524233B2 (en) * 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
BR112020017445A2 (pt) * 2018-02-27 2021-01-26 Equillium, Inc. anticorpos anti cd6 para tratar asma severa
US20230044958A1 (en) * 2019-12-24 2023-02-09 Hoffmann-La Roche Inc. Method of treating virus infection using a tlr7 agonist

Also Published As

Publication number Publication date
KR20220165267A (ko) 2022-12-14
CA3174566A1 (en) 2021-10-07
EP4126961A1 (en) 2023-02-08
CL2022002684A1 (es) 2023-03-24
US20230151107A1 (en) 2023-05-18
WO2021199006A1 (en) 2021-10-07
CN115698071A (zh) 2023-02-03
TW202200202A (zh) 2022-01-01
MX2022012229A (es) 2022-10-27
JP2023526890A (ja) 2023-06-26
AU2021247258A1 (en) 2022-11-10
BR112022018936A2 (pt) 2022-12-06
IL296487A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
BR112022002150A2 (pt) Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CO2022000481A2 (es) Inhibidores de enzimas
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2022000266A2 (es) Inhibidores de enzimas
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2022014199A2 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19
NI202000085A (es) Moduladores de la expresión de apol1
CO2022000270A2 (es) Inhibidores de enzimas
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
BR112022000957A2 (pt) Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno
CL2022000214A1 (es) Inhibidores de enzimas
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria